From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Joschka
J
Lorenz
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Johannes
J
Waldschmidt
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Dagmar
D
Wider
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Marie
M
Follo
Clinical Trials Centre, University Medical Centre Freiburg, Freiburg, Germany.
Gabriele
G
Ihorst
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Manik
M
Chatterjee
Institute of Pathology, University of Freiburg Medical Centre, Freiburg, Germany.
Annette M
AM
May
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Justus
J
Duyster
Institute of Pathology, University Hospital Würzburg, Würzburg, Germany.
Andreas
A
Rosenwald
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Ralph
R
Wäsch
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany.
Katja
K
Zirlik
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, Freiburg, Germany. monika.engelhardt@uniklinik-freiburg.de.
Monika
M
Engelhardt
D000328:Adult; D000368:Aged; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use; D000072377:Syk Kinase / Q000032:analysis / Q000037:antagonists & inhibitors* / Q000494:pharmacology
C510788:N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine; D010078:Oxazines; D047428:Protein Kinase Inhibitors; D011725:Pyridines; C000606896:SYK protein, human; D000072377:Syk Kinase
R406; chronic lymphocytic leukemia; multiple myeloma; spleen tyrosine kinase; therapy